Relay Therapeutics
RLAY
About: Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
Employees: 197
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
39% more capital invested
Capital invested by funds: $427M [Q1] → $592M (+$165M) [Q2]
37% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 54
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
3.74% more ownership
Funds ownership: 96.0% [Q1] → 99.73% (+3.74%) [Q2]
0% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 34
0% less funds holding
Funds holding: 207 [Q1] → 206 (-1) [Q2]
99% less call options, than puts
Call options by funds: $1K | Put options by funds: $128K
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
|
Guggenheim
Brad Canino
|
$15
|
Buy
Assumed
|
4 Sep 2025 |
|
HC Wainwright & Co.
Robert Burns
|
$14
|
Buy
Maintained
|
26 Aug 2025 |
|
Raymond James
Dane Leone
|
$19
|
Strong Buy
Maintained
|
8 Aug 2025 |
Financial journalist opinion
Based on 4 articles about RLAY published over the past 30 days
